Unveiling 6 Analyst Insights On Kymera Therapeutics
Unveiling 6 Analyst Insights On Kymera Therapeutics
揭示Kymera Therapeutics的6个分析师见解
Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Kymera Therapeutics (NASDAQ:KYMR) in the last three months.
在过去三个月中，有6位分析师公布了对Kymera Therapeutics（纳斯达克股票代码：KYMR）的评级，提供了从看涨到看跌的不同视角。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
下表汇总了他们最近的评级，阐明了过去30天内情绪的变化，并将其与前几个月进行了比较。
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $44.0, along with a high estimate of $52.00 and a low estimate of $36.00. This upward trend is apparent, with the current average reflecting a 5.19% increase from the previous average price target of $41.83.
分析师提供了更深入的见解，确定了12个月的目标股价，平均目标价为44.0美元，最高估计为52.00美元，低估值为36.00美元。这种上升趋势显而易见，当前的平均价格较之前的平均目标价41.83美元上涨了5.19％。
Breaking Down Analyst Ratings: A Detailed Examination
分解分析师评级：详细审查
The...
对...
登录免费看全文
登录/注册